微信编辑 | 苏小 第一财经持续追踪财经热点。若您掌握公司动态、行业趋势、金融事件等有价值的线索，欢迎提供。 专用邮箱：bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 2026.01. 19 本文字数：510，阅读时长大约1分钟 来源 | 证监会浙江证监局 证监会浙江证监局发布行政处罚决定书，2024年9月2日至2025年4月16日，金永荣知晓其荐股行为具有影响力，在其雪球"金浤"账号公开发文评价、 推荐"启迪环境""路维光电""光华科技"等32只股票，并控制账户组在荐股后的当日或次日进行大量反向卖出交易。按当日及次日卖出口径计算，交易金 额合计630,594,337.30元，违法所得合计41,623,864.21元。 金永荣对证券、发行人公开作出评价、推荐并进行反向证券交易，影响或意图影响证券交易价格或者证券交易量，违反《证券法》第五十五条第一款第六项规 定，构成《证券法》第一百九十二条所述违法行为。 证监会浙江证监局决定对金永荣采取3年证券市场禁入措施，自宣布决定之日起，在禁入期间内，不得直接或者以化名、借他人名义在证券交易场所交易上市或者 挂牌的所有证券。 推荐 ...

证监会浙江证监局发布行政处罚决定书，2024年9月2日至2025年4月16日，当事人金永荣知晓其荐股行 为具有影响力，在其雪球"金浤"账号公开发文评价、推荐"启迪环境""路维光电""光华科技"等32只股 票，并控制账户组在荐股后的当日或次日进行大量反向卖出交易。按当日及次日卖出口径计算，交易金 额合计630,594,337.30元，违法所得合计41,623,864.21元。鉴于当事人金永荣操纵证券市场的违法行为影 响证券交易秩序，情节严重，我局决定：对金永荣采取3年证券市场禁入措施，自我局宣布决定之日 起，在禁入期间内，不得直接或者以化名、借他人名义在证券交易场所交易上市或者挂牌的所有证券。 ...

这也是第二批有望获赔的文峰股份股民。 2024年9月，南京中院就原告刘某某、周某某等4名自然人投资者与徐翔、徐长江、文峰股份操纵证券市场责任纠纷一案作出一审判决，要求被告徐翔、徐 长江赔偿合计损失110.26万元；文峰股份对上述赔偿义务承担连带责任，并在实际承担责任后有权向被告徐翔、徐长江追偿。 文峰股份因不服南京中院上述判决，向江苏省高级人民法院（下称"江苏高院"）提起上诉。此后，江苏高院终审判决相关赔偿不变；变更一审判决第二项 为"文峰股份对徐翔、徐长江上述第一项赔偿义务承担连带赔偿责任"。 一则诉讼进展公告，让前私募大佬徐翔再度进入公众视野。 文峰股份（601010）1月5日晚间披露，公司收到江苏省南京市中级人民法院（下称"南京中院"）送达的《民事判决书》，南京中院就新增投资者诉讼事项 作出一审判决。 判决结果显示，被告徐翔、徐长江于判决发生法律效力之日起十日内向原告敖某某等23人赔偿损失合计329.36万元；被告文峰股份对被告徐翔、徐长江上 述第一项赔偿义务承担连带赔偿责任。案件受理费合计4.12万元，由徐翔、徐长江、文峰股份共同负担；公告费以实际支出为准，由徐翔负担。 文峰股份表示，公司将在法定上诉 ...

【导读】徐翔、徐长江 判赔23 名投资者 329.36 万元 中国基金报记者 孙越 昔日私募大佬徐翔、文峰股份前董事长徐长江，再次因操纵证券市场，被法院一审判决赔偿 投资者损失。一审判决结果显示，徐翔、徐长江需向 23 名投资者赔偿损失合计 329.36 万 元，文峰股份对此承担连带赔偿责任。 公开资料显示，徐翔、徐长江于 2017 年均被判决操纵证券市场罪，文峰股份也因信息披露 违法受到行政处罚。此后，部分投资者陆续对徐翔、徐长江等相关责任方发起民事索赔。 23 名投资者有望获赔超 300 万 1 月 5 日晚间，文峰股份发布公告称，公司收到江苏省南京市中级人民法院送达的《民事判 决书》，再次卷入与前 " 私募一哥 " 徐翔及公司前董事长徐长江相关的操纵证券市场民事赔 偿案。 根据公告，敖某某等 24 名投资者起诉徐翔、徐长江及文峰股份，指控徐翔与徐长江合谋实施 操纵证券交易市场行为，文峰股份则配合发布影响股价的重大信息，存在帮助行为，应承担 连带赔偿责任。 一审判决结果显示，其中一名原告的诉讼已超过诉讼时效，被法院驳回；徐翔、徐长江需向 其余 23 名投资者赔偿损失合计 329.36 万元，文峰股份对此承 ...

Core Viewpoint - Zhongheng Electric (002364.SZ) announced that its actual controller, Zhu Guoding, received a criminal judgment from the Hangzhou Intermediate People's Court, indicating legal issues related to market manipulation [1][2]. Group 1: Legal Proceedings - Zhu Guoding was sentenced to three years in prison, with a four-year probation, and fined 1 million RMB for the crime of manipulating the securities market [2]. - The case has been ongoing since August 2020, when the company disclosed that Zhu was under investigation by the China Securities Regulatory Commission for suspected stock price manipulation [1][2]. Group 2: Shareholder Information - As of September 30, 2025, major shareholders include Hangzhou Zhongheng Technology Investment Co., Ltd. with 200,389,724 shares (35.905% of circulating shares) and Shanghai Pudong Development Bank's fund with 9,432,900 shares (1.690%) [3]. - Other significant shareholders include Shenzhen Zhanbo Investment Management Co., Ltd. with 5,374,584 shares (0.963%) [3].

Core Viewpoint - The recent court ruling has brought former private equity figure Xu Xiang back into the public eye, with the court ordering Xu and his associate to compensate investors for losses related to market manipulation [2][3]. Group 1: Court Ruling and Compensation - Wanfeng Co., Ltd. received a civil judgment from the Nanjing Intermediate People's Court, requiring Xu Xiang and Xu Changjiang to pay a total of 3.2936 million yuan to 23 plaintiffs [2]. - Wanfeng Co., Ltd. is held jointly liable for the compensation obligations of Xu Xiang and Xu Changjiang, with a total litigation fee of 41,200 yuan to be shared among the defendants [2][3]. - The plaintiffs, originally 24 investors, sought a total compensation of 3.3278 million yuan, but one claim was dismissed due to exceeding the statute of limitations [3]. Group 2: Previous Cases and Legal Context - This ruling follows a previous case where four investors were awarded 1.1026 million yuan in damages, with Wanfeng Co., Ltd. also held jointly liable [4]. - The court found that Xu Xiang and Xu Changjiang had conspired to manipulate the stock market, with Wanfeng Co., Ltd. facilitating the release of significant information that affected stock prices [3][4]. - Xu Xiang and Xu Changjiang were previously convicted of market manipulation, and Wanfeng Co., Ltd. faced administrative penalties for information disclosure violations [6]. Group 3: Financial Implications and Investor Losses - Xu Xiang reportedly profited 454 million yuan from trading Wanfeng Co., Ltd. shares, while Xu Changjiang's total cash-out from stock sales reached 6.762 billion yuan [5][6]. - As of now, a total of 1,015 investors have filed lawsuits against Xu Xiang, Xu Changjiang, and Wanfeng Co., Ltd., with estimated total investor losses amounting to approximately 86.7439 million yuan [6].

Core Viewpoint - Zhao Yeqing, the actual controller of Jincheng Pharmaceutical, has been penalized for stock manipulation, leading to his resignation as chairman and director of the company [1][5]. Group 1: Stock Manipulation Case - From August 18, 2017, to February 10, 2020, Zhao Yeqing, Wang Zhen, and Liu Feng collectively manipulated Jincheng Pharmaceutical's stock, with Zhao being the decision-maker [2][4]. - During the manipulation period of 595 trading days, the account group participated in trading for 502 days, buying 119 million shares for a total of 2.134 billion yuan and selling 107 million shares for 1.87 billion yuan, resulting in an actual loss of 7.392 million yuan [2][3]. - The regulatory authority imposed a total fine of 3 million yuan on the three individuals, with Zhao Yeqing responsible for 1.5 million yuan, and he received a four-year market ban [4][5]. Group 2: Company Performance and Developments - Jincheng Pharmaceutical, founded in 2004, has evolved into a company with five strategic business areas, including pharmaceutical chemicals and synthetic biology [8]. - The company has experienced fluctuating performance, with revenues of 3.538 billion yuan and 3.373 billion yuan in 2023 and 2024, respectively, and a significant decline in net profit by 79.1% in the first three quarters of 2025 [9]. - A collaboration project with Giskit Pharma for a drug related to female infertility was terminated due to lack of progress and failure to reach a formal agreement [10][11].

12月11日，山东金城医药集团股份有限公司（300233.SZ）连发两则公告，揭开实控人带头操纵股价案的终局：董事长赵叶青因主导长达近三年的股票操 纵行为，被证监会罚款150万元并实施4年市场禁入，当日其已正式辞去公司所有职务。 据证监会查明，2017年8月18日至2020年2月10日期间，赵叶青作为决策者，与王震（主要实施者）、刘峰（次要实施者）共同操纵了"金城医药"股票。 根据公告，赵叶青、王震、刘峰三人控制使用104个证券账户，通过集中资金优势、持股优势连续买卖，在自己实际控制的账户之间进行交易等手段操 纵"金城医药"股票，影响"金城医药"股票交易价格和交易量。 操纵期间共595个交易日，账户组在502天参与交易，累计竞价买入1.19亿股，金额21.34亿元，累计竞价卖出1.07亿股，金额18.70亿元。尽管实施了操纵行 为，账户组最终亏损约739.2万元。 具体而言，账户组期初持有"金城医药"8300股，期末持有1177.63万股。操纵期间，账户组日均持有"金城医药"1858.33万股，占流通股本的5.68%，最高持 股3209.48万股，占流通股本的9.04%。账户组累计竞价买入约1.19亿股，卖出 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation and imposed administrative penalties on Zhao Yeqing, Wang Zhen, and Liu Feng for manipulating the stock of Shandong Jincheng Pharmaceutical Group Co., Ltd. [1] Group 1: Investigation and Penalties - The investigation revealed that the three individuals manipulated the stock market from August 18, 2017, to February 10, 2020, by controlling 104 accounts to influence stock trading prices and volumes [1] - Zhao Yeqing was fined 1.5 million yuan and banned from the market for 4 years, while Wang Zhen was fined 1.2 million yuan with a 3-year market ban, and Liu Feng was fined 300,000 yuan [1]

中国经济网北京12月12日讯 金城医药(300233.SZ)今日发布关于公司实际控制人收到行政处罚决定书的公 告。2025年12月10日，公司收到实际控制人赵叶青的通知，其收到中国证监会《行政处罚决定书》（处罚字 ﹝2025﹞147号），主要内容如下： 经查明，当事人存在以下违法事实：2017年8月18日至2020年2月10日(以下简称操纵期间)，赵叶青、王 震、刘峰3人共同操纵"金城医药"股票。其中，赵叶青是操纵行为的决策者，王震是操纵行为的主要实施者，刘 峰是操纵行为的次要实施者。 一、控制使用证券账户情况 根据当事人自认、他人指认、证券账户开户资料及情况说明、证券及银行账户资金往来记录、证券账户交 易流水等证据，操纵期间赵叶青、王震、刘峰控制使用相关账户组共104个账户交易"金城医药"股票。 经测算，账户组实际亏损7,392,044.45元。 赵叶青、王震、刘峰的上述行为违反2005年《证券法》第七十七条第一款第一项、第三项的规定，构成 2005年《证券法》第二百零三条所述操纵证券市场的违法行为。根据当事人违法行为的事实、性质、情节与社 会危害程度，中国证监会决定: 一、依据2005年《证券法》第二百零 ...